Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
AIDX · NASDAQ · Services-Testing Laboratories
20/20 Biolabs (AIDX) · oqro.io/stocks/AIDX · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$0.1571−0.0235 (−13.01%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of 20/20 Biolabs is on record in SEC filings since 2006.
No open-market sale by an insider of 20/20 Biolabs (AIDX) was filed with the SEC in the last 90 days.
No trade in 20/20 Biolabs (AIDX) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−99.3% (−$23.69) from Feb 19, 2026 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $23.85 on Feb 19, 2026 to $0.1571 on Nov 20, 2026 (−99.3%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Services-Testing Laboratories company based in Rockville, Md.
Last 12 months
Not enough history
Market value
$2.01M
Short interest: 57K shares sold short (0.4% of shares outstanding), +405.8% vs the previous count, 1.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2025
$2.05M
+16.7% vs the year before
Net income, fiscal 2025
−$3.74M
A loss for the year
Shares outstanding
12.8M
As of Aug 14, 2026
Nothing reported yet
New filings show up here as soon as they are processed.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Revenue
$380K
−9.0% vs the same quarter a year earlier
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $3.63M, at Sep 30, 2026
Net income, last 12 months
−$6.36M
Operating loss: profit did not cover interest
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 16, 2026.
The three months Jul 1, 2026 to Sep 30, 2026, compared with the same quarter a year earlier, from the quarterly report filed Nov 16, 2026. Quarterly reports are not audited. Read the filing
−2.2% on the same quarter a year earlier ($361K)
−24% on the same quarter a year earlier ($36K)
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Mar 31, 2026. Read the filing
+21% on the year before ($1.49M)
−14% on the year before ($177K)
+6.2% on the year before ($84K)
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 9,000 words.
We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, an MCED, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that was launched in February 2026 (the Longevity test is also being branded “OneTest for Workplace Wellness” when marketed to self-insured employers). Both tests are run in our CAP accredited, CLIA licensed laboratory in Gaithersburg, MD. This laboratory also hosts our CLIAx, which we believe is the country’s first shared CLIA laboratory for overseas diagnostics start-ups seeking to launch novel lab tests in the U.S.
Source: SEC EDGAR, Form 10-K filed Mar 31, 2026 and Form 10-Q filed Nov 16, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Off-exchange trading: 69.3% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (4.8% on ATS, 64.5% with other brokers), above its 26-week average of 48.2%. Weeks of Sep 21 to Oct 16, 2026.
And 6 more headings in the filing.
Largest ATS: VIRTU MATCHIT ATS (19.7%), POSIT (13.6%), SIGMA X2 (10.7%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Against the S&P 500 over the year
Since Feb 19, 2026, AIDX is down 99.3% and the index fund is up 0.8%: 100 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much AIDX moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.
Latest annual report filed Mar 31, 2026. Read the filing
53 risk factor headings in this report. There is no earlier annual report to compare it with.
From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating results.
Source: SEC EDGAR, Form 10-K filed Mar 31, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
No Schedule 13D or 13G filing on AIDX over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
Notice of delisting or failure to meet listing rules
8-K on sec.govNotice of delisting or failure to meet listing rules
8-K on sec.govSaid its annual or quarterly report would be late
NT 10-Q on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.